We aimed to describe the use of venovenous extracorporeal carbon dioxide removal (ECCO 2 R) in patients with hypercapnic respiratory failure. We performed a retrospective case note review of patients admitted to our tertiary regional intensive care unit and commenced on ECCO 2 R from August 2013 to February 2015. Fourteen patients received ECCO 2 R. Demographic data, physiologic data (including pH and partial pressure of carbon dioxide in arterial blood [PaCO 2 ]) when starting ECCO 2 R (t = 0), at 4 hourly intervals for the first 24 hours, then at 24 hour intervals until cessation of ECCO 2 R, and overall outcome were recorded. Patients are reported separately depending on whether the indication for ECCO 2 R was an exacerbation of chronic obstructive pulmonary disease (COPD; n = 5), or acute respiratory distress syndrome (ARDS) and persisting hypercapnoea (n = 9). Patients were managed with ECCO 2 R (Hemolung, ALung Inc, Pittsburgh, PA). Median duration of ECCO 2 R was 5 days. Four complications related to ECCO 2 R were reported, none resulting in serious adverse outcomes. Ten patients were discharged from intensive care unit (ICU) alive. A statistically significant improvement in pH (p = 0.012) was demonstrated. Our observational series of ECCO 2 R shows that this technique can be safely used to achieve therapeutic goals in patients requiring lung protection, and in COPD, in line with current publications in this area. ASAIO Journal 2016; 62:458-462.
Extracorporeal carbon dioxide removal (ECCO 2 R) uses membrane oxygenators at low blood flows (400-600 ml/minute) to provide partial respiratory support by removing carbon dioxide (CO 2 ) while providing minimal systemic oxygenation. This is enabled by the high solubility of CO 2 in blood. The earliest generation of dedicated devices were arteriovenous (AV), however, recent technological improvements have led to the development of pumped venovenous (VV) systems. Percutaneously inserted dual lumen venous cannulae are used to access the circulation and CO 2 removal is achieved through high efficiency gas exchange membranes. [1] [2] [3] The goal of selective CO 2 removal is to provide partial respiratory support to allow a reduction in alveolar minute ventilation. In patients with acute respiratory distress syndrome (ARDS), tidal volumes of 6 ml/kg and plateau pressures <28-30 cm H 2 O 4 are known to improve mortality. Furthermore higher ventilator driving pressure is associated with increased mortality in patients with ARDS. 5 However, even with lung protective strategies, mortality exceeds 50%. 6 One of the barriers to using lung protective ventilation is that reducing tidal ventilation can result in hypercapnoea. There is some evidence suggesting that ECCO 2 R may facilitate lower volumes, lower plateau pressures, and lower driving pressures by controlling hypercapnoea. [7] [8] [9] The other patient cohort where ECCO 2 R is promising is in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) leading to hypercapnic respiratory failure. In these patients, the current gold standard therapy is noninvasive ventilation (NIV). However, patients who fail NIV and require invasive mechanical ventilation have a significantly higher mortality. 10 Extracorporeal carbon dioxide removal has been demonstrated to provide physiologic benefit for patients with COPD by increasing pH, reducing PaCO 2 , reducing respiratory rate, and minute ventilation. Extracorporeal carbon dioxide removal has been used to prevent intubation and to facilitate early extubation in patients with acute exacerbations of COPD. 1, 11 Although the impact of CO 2 removal on work of breathing has not been directly studied, ECCO 2 R is associated with reduced subjective dyspnoea. 11 Furthermore, although there is yet to be a randomized controlled trial of ECCO 2 R in COPD, a recent propensity matched retrospective cohort study demonstrated a reduction in mortality associated with ECCO 2 R for NIV failure in COPD. 12 The aim of the current study was to explore the physiologic changes and outcomes in a cohort of patients commenced on ECCO 2 R for a variety of indications in a tertiary intensive care unit (ICU).
Materials and Methods
We performed a retrospective, observational, electronic case-note review of all patients commenced on ECCO 2 R by the attending clinician from August 2013 to February 2015. Cases were identified through a prospectively maintained electronic Demographic data collected included age, gender, ethnicity, primary admission diagnosis, cause of respiratory failure, and any known comorbidities. Physiologic data collected included ventilator settings, associated organ system support (vasopressor therapy or renal replacement therapy), and specific data related to ECCO 2 R use. Cannulation method and site, pump settings, and anticoagulation method were recorded. Full blood counts, arterial blood gases, and ventilation settings were gathered just before starting ECCO 2 R, at 4 hourly intervals for the first 24 hours and at 24 hourly intervals until cessation of ECCO 2 R.
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Complications recorded included significant bleeding (defined as a transfusion requirement of more than 2 units of packed red blood cells or intracranial haemorrhage), haemolysis (plasma-free hemoglobin [PfHb] >0.5 g/l), circuit failure, or cannula thrombosis. The method and duration of ventilatory support and overall patient outcome were also recorded.
All data were analyzed using Graphpad Prism software. We performed a Shapiro-Wilk normality test on all data to assess distribution. We made no assumption of sphericity of data, and the Geisser-Greenhouse correction was used. For parametrically distributed data, a one-way repeated measure ANOVA analysis was performed, followed by Dunnett's multiple comparison's test. For non-normally distributed data, a nonparametric repeat measure tool (Friedman test) was used.
Results

Demographic Data
During our study period, 14 patients were identified who received ECCO 2 R. Demographic data are in Tables 1 and 2. 50% of patients were female and the overall cohort had a median age of 60.5 years (range: 29-78; Table 1 ). The etiology of respiratory failure is recorded in Table 2 . Just over a third of cases (5/14) were commenced on ECCO 2 R for an exacerbation of COPD, either for intubation avoidance (3/5) or to facilitate early extubation (2/5). In the remaining cases (9/14), ECCO 2 R was initiated to facilitate lung protective ventilation. The overall hospital survival was 71% (10/14)-4/5 patients with COPD survived to hospital discharge and 6/9 patients with ARDS survived. The differences between survivors and nonsurvivors are shown in Table 3 .
All patients were managed with ECCO 2 R using Hemolung (Alung Inc, Pittsburgh, PA) via a 15.5 FG percutaneously inserted cannula, of which five (36%) were sited in the femoral vein, and nine (64%) were sited in the internal jugular vein. There were no recorded complications of cannulation.
The median duration of ECCO 2 R was 5 days (range: 4-19 days). The median total duration of ventilatory support during the ICU stay was 1 day (0-5 days) NIV, and 41.5 days (5-66 days) mechanical ventilation.
Physiologic Data
We initially analyzed the data individually for the subpopulations of COPD and non-COPD patients, but the small sample size precluded any meaningful statistical analysis. Across the entire cohort of 14 patients, using the Shapiro-Wilk normality test, both pH and PaCO 2 were shown to be normally distributed. There was a statistically significant improvement in pH (p = 0.012) at all time points except 12 hours post commencement ( Figure 1A) . The overall change in PaCO 2 was nonsignificant (p = 0.262), with the only statistically significant change in PaCO 2 observed at t = 4 hours (Figure 1B) .
For the COPD cohort, there was an apparent reduction in respiratory rate and rise in pH in patients commenced on ECCO 2 R (Figure 2) , although this did not reach statistical significance. Two of three patients avoided intubation, and in the two patients in whom tracheal extubation was the goal, one was extubated within 48 hours, the other within 4 days of ECCO 2 R commencement. Following the commencement of ECCO 2 R in patients with ARDS (Figure 3) , there was a sustained reduction in peak inspiratory pressures, and an increased positive end-expiratory pressure (PEEP) was required to maintain mean airway pressure and oxygenation, resulting in a reduction in driving pressure. The changes seen were not statistically significant.
Hemoglobin and platelet count were shown to be normally distributed, whereas bilirubin was not. There was a statistically significant reduction in both Hb (p = 0.006) and platelet count (p = 0.0004) in the first 72 hours of ECCO 2 R therapy (Figure 4A, B) . Bilirubin did not change significantly during the first 72 hours (p = 0.065; Figure 4C ).
There were four circuit-related complications recorded. Two circuit changes were undertaken due to falling membrane CO 2 clearance, and there were also two episodes of hemolysis that resolved on discontinuation of ECCO 2 R with no further sequelae. One episode of hemolysis presented within 24 hours as frank hematuria, the other presented at day 6 following ECCO 2 R commencement. There were no cases of significant bleeding, air entrainment, or cannula thrombosis identified.
DISCUSSION
There were a total of 14 cases of venovenous ECCO 2 R for respiratory failure (five COPD, nine ARDS). The approach demonstrated allowed for a statistically significant improvement in pH for both patient cohorts. In addition, there was an apparent reduction in peak and driving pressure for the ARDS group and in respiratory rate for the COPD group, although neither change reached statistical significance. Other than transient hemolysis in two patients, no harm was recorded and there was no lasting adverse effect of therapy. Survival to hospital discharge was excellent at 71%, compared with expected mortality for this population of patients from the literature being 67.5%. 13 Although there is good evidence supporting a strategy of reduced plateau pressure and tidal volume to improve mortality, 9 the mortality for moderate to severe ARDS remains high. 6, 14 Furthermore, there is some evidence suggesting that tidal volumes of under 6 ml/kg ideal body weight with a plateau pressure less than 28 cm H 2 O are beneficial. 15 Another important element appears to be the driving pressure (peak pressure-PEEP), which is associated with mortality. 5 Recent studies have successfully used ECCO 2 R to facilitate lung protective ventilation. 8, 9 Our results are in keeping with this study; although statistical significance was not reached, we demonstrated a trend toward reduced driving pressures in our cohort of patients with ARDS using low blood flow venovenous ECCO 2 R (median blood flow of 0.5 l/minute). When titrating ECCO 2 R, sweep gas flow was titrated against CO 2 clearance to achieve a pH > 7.35. In our series, there was a median of 10 days of mechanical ventilation before the commencement of ECCO 2 R. There is growing evidence that delays in commencing extracorporeal membrane oxygenation (ECMO) beyond 6 days is a prognostic indicator for mortality. 16 The same data are not available for ECCO 2 R, however it would seem reasonable that the same relationship applies. It is possible that our cohort may have benefited from earlier application of the therapy. However, due to the lack of evidence supporting the technique, clinicians ensured that all other options were explored first. Given the size of the cohort, it is difficult to make meaningful interpretations of mortality, however it is in keeping with results from other studies. 6, 14 Finally, it is not currently known how long patients should remain on ECCO 2 R to receive benefit from the therapy; in this case, clinical benefit was deemed to have taken a median of 5 days, although the range was up to 19 days. This is important for future trials considering the correct "duration" of ECCO 2 R in the ARDS population.
In the COPD cohort, treatment goals were achieved for 80% patients. The only patient who did not reach their treatment goal was a patient with an influenza A-induced exacerbation of COPD for whom intubation was avoided for 6 days of therapy; however, hemolysis occurred leading to cessation of the device and the patient was subsequently intubated. Ventilatory strategy was not uniform for all COPD patients before commencement of ECCO 2 R: two patients were already intubated at commencement of therapy, two patients failed NIV, and one patient did not tolerate NIV. Patients were managed with a median blood flow of 0.44 l/minute and for a median of 5 days with the sweep gas flow rate titrated to arterial CO 2 for a pH > 7.35. As demonstrated in Figure 2 , the respiratory rate and hence work of breathing reduced rapidly following institution of ECCO 2 R, associated with a reduction in PaCO 2 and improvement in pH. This is in keeping with other studies using both AV and VV ECCO 2 R. 2, 11 The precise physiologic impact of ECCO 2 R on the respiratory system is not known, but it is likely that a reduced respiratory rate allows more effective expiration, which in turn allows unloading of the muscles of respiration. Reduced respiratory rate also presumably contributes to reduced patient exhaustion. Therapy was well tolerated by patients and facilitated an oral diet, communication, and mobilization out of bed. These were achieved through the removal of NIV and tracheal extubation. For patients with this severity of COPD, who have failed NIV, the ICU length of stay was relatively short at a median of 7 days. 17 It is difficult to make meaningful comments on mortality in this cohort given the size of the study, however it is in keeping with mortality reported in other studies of ECCO 2 R in severe COPD exacerbation.
In two of the patients who died, although ECCO 2 R was commenced to facilitate extubation for one case and prevent intubation in the other, once respiratory distress was eased ECCO 2 R facilitated autonomous decision-making by the patient which resulted in palliative care being instituted at the patient's request. The use of extracorporeal support allowed the patients to spend quality time with their families before their deaths. It is known that the provision of good end of life care on the patient has a significant impact on relatives, reducing anxiety, stress, and depression. 18, 19 There is little data available on the impact of pumped VV ECCO 2 R systems on hematology. However, the hematological effects of ECMO are better understood and include an acquired thrombocytopenia, reduction in a variety of coagulation factors, and potentially an acquired von Willebrand's factor deficiency. 20 These changes are believed to occur as a result of both adsorption of proteins and blood cellular components onto the artificial surface, proinflammatory effects of the circuit, and physical trauma to the blood caused by passage through the pump and membrane lung. [21] [22] [23] In the current series, there was a progressive thrombocytopenia (defined as a >50% reduction from baseline levels in keeping with diagnostic criteria for other conditions 24 ) in keeping with previous ECMO studies and with previous animal studies using the same device. 25 There was no bleeding associated with this degree of thrombocytopenia despite the simultaneous presence of moderate anticoagulation with heparin. A mild anaemia was also noted; this may be due to dilution from the circuit priming volume (approximately 400 ml) and did not appear to be related to haemolysis. Hemolysis was only found in two cases and no change in bilirubin was identified (unfortunately pfHb was not measured consistently in all patients as a measure of hemolysis). Again this appears to be in keeping with other publications using this device 25 as well as the general ICU literature where anemia is routinely reported. 26 There were no complications of cannulation. Acute cannula thrombosis has occurred in another hospital (personal communication), but did not occur in this series. It is possible that the reported case of thrombosis was a rare event, or that the administration of heparinised saline flush at the time of cannulation prevented this from occurring. No cannula site infections were recorded despite cannulae being in place for a median of 5 days, a maximum of 19 days, and a third of cannulae being placed in femoral vessels. Cannula infection is relatively common in the ICU literature, 27 and it is unclear whether the low rate of infection relates to the approach taken for cannulation or to ongoing cannula care.
The current study has significant limitations. It is an uncontrolled, small study with retrospective data collection and therefore has inherent bias, including selection bias and missing information. The study is small preventing meaningful statistical comparisons for much of the data and the clinical diagnoses show significant variability. Nevertheless the cohort is valuable as it is one of the first reports of ECCO 2 R outcomes in clinical practice.
Conclusions
Our retrospective, observational series of ECCO 2 R shows that this is a promising technique for the management of patients with severe exacerbations of COPD and for achieving lung protective ventilation in patients with ARDS without refractory hypoxaemia. Venovenous ECCO 2 R can provide improved physiologic control of gas exchange with minimal complications.
